A Phase II trial is underway for Tefina, a testosterone-based treatment for female sexual dysfunction.
A Phase II trial is underway for Tefina, a testosterone-based treatment for female sexual dysfunction. Nicknamed “the female Viagra,” the drug is administered via a nasal spray two hours before sexual activity, and is believed to increase desire and stimulate blood flow to the sexual organs, making it appropriate for both women with low desire as well as women with difficulty climaxing.
One fertility specialist, Ric Gordon, said he believed that the drug was “exploiting” female sexuality, because it overlooked the reasons behind a low sexual drive. He maintained that “men use sex to de-stress and women need to be de-stressed to have sex,” and so by bringing this drug to market, more complicated emotional issues will be ignored
Online Poll
|
Online Survey
Please add your thoughts in the Comments section below.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Study finds pregnancy risks higher with ART in kidney transplant recipients
July 11th 2025Women with kidney transplants who conceive through assisted reproductive technology face increased risks of complications such as hypertension, preterm birth, and cesarean delivery, according to new research.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen